<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942344</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ALOS-201</org_study_id>
    <nct_id>NCT00942344</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension</brief_title>
  <official_title>An 8-week, Multicenter, Randomized, Double-blind, Factorial Phase II Study to Evaluate Dose-response Relationship of Amlodipine and Losartan Combination in Patients With Essential Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of fixed combination of
      amlodipine(5mg or 10mg) and losartan (50 mg or 100 mg), amlodipine and losartan alone in
      reducing blood pressure. The study will investigate the dose response relationship for the
      combinations and monotherapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average changes from baseline in sitDBP</measure>
    <time_frame>Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average changes from baseline in sitDBP</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average changes from baseline in sitSBP</measure>
    <time_frame>Week 4, 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure responder rate</measure>
    <time_frame>Week 4, 8</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">320</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine plus Losartan</intervention_name>
    <description>amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg</description>
    <other_name>Amosartan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>amlodipine 5mg, 10mg</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan 50mg, 100mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 18 and 75

          -  Patients with essential hypertension {95 mmHg ≤ sitDBP&lt; 115 mmHg at the end of placebo
             run-in treatment period}

        Exclusion Criteria:

          -  Patients with mean sitSBP ≥ 200 mmHg

          -  Patients with known hypersensitivity to Dihydropyridine or angiotensin II receptor
             blockers

          -  Patients with secondary hypertension or suspected secondary hypertension

          -  Patients with malignant hypertension

          -  Patients who have received any medications with possible interactions with study drugs

          -  Patients with uncontrolled diabetes

          -  Patients with severe heart disease or severe cerebrovascular disease

          -  Patients with clinically significant hematological test results, renal disease (serum
             creatinine) or liver disease (ALT or AST)

          -  Patients with a history of malignant disease

          -  Patients with a history of autoimmune disease

          -  Women with a positive pregnancy test result, breast feeding or intention of pregnancy
             during the trial

          -  Patients inappropriate to be included in study population due to other reasons at the
             discretion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Yun Cho, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>14 sites in Korea</name>
      <address>
        <city>Seoul, Busan, etc.</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2009</study_first_submitted>
  <study_first_submitted_qc>July 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2009</study_first_posted>
  <last_update_submitted>July 17, 2009</last_update_submitted>
  <last_update_submitted_qc>July 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Hanmi Pharmaceutical Company Limited</organization>
  </responsible_party>
  <keyword>Amlodipine</keyword>
  <keyword>Losartan</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

